1. Home
  2. ECPG vs XERS Comparison

ECPG vs XERS Comparison

Compare ECPG & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Encore Capital Group Inc

ECPG

Encore Capital Group Inc

HOLD

Current Price

$95.00

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$8.23

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECPG
XERS
Founded
1998
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
ECPG
XERS
Price
$95.00
$8.23
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$77.33
$10.83
AVG Volume (30 Days)
324.4K
1.9M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
287.14
100.00
EPS
3.86
0.01
Revenue
$1,768,802,000.00
$49,590,000.00
Revenue This Year
$4.53
$34.37
Revenue Next Year
$4.76
$22.86
P/E Ratio
$24.47
$821.00
Revenue Growth
34.37
142.67
52 Week Low
$35.68
$4.87
52 Week High
$94.60
$10.08

Technical Indicators

Market Signals
Indicator
ECPG
XERS
Relative Strength Index (RSI) 62.55 54.38
Support Level $77.69 $8.00
Resistance Level N/A $8.42
Average True Range (ATR) 3.23 0.33
MACD 0.05 -0.11
Stochastic Oscillator 80.56 24.00

Price Performance

Historical Comparison
ECPG
XERS

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: